{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:56Z","timestamp":1772119976376,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020207","name":"Health Commission of Sichuan Province","doi-asserted-by":"crossref","award":["No. 21PJ149"],"award-info":[{"award-number":["No. 21PJ149"]}],"id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12012-025-10066-8","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T18:57:10Z","timestamp":1760727430000},"page":"1927-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"25","author":[{"given":"Changyu","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guimu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiXuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiguang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"32 Suppl","key":"10066_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000069105","volume":"3","author":"H Ikoma","year":"2002","unstructured":"Ikoma, H. (2002). Development of argatroban as an anticoagulant and antithrombin agent in Japan. Pathophysiology of Haemostasis and Thrombosis, 3(32 Suppl), 23\u201328.","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"2 Suppl","key":"10066_CR2","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012). Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis,9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 Suppl), e24S-e43S.","journal-title":"Chest"},{"issue":"2","key":"10066_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10557-020-07066-x","volume":"35","author":"KF Aliter","year":"2021","unstructured":"Aliter, K. F., & Al-Horani, R. A. (2021). Thrombin inhibition by argatroban: Potential therapeutic benefits in COVID-19. Cardiovascular Drugs and Therapy, 35(2), 195\u2013203.","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"7","key":"10066_CR4","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1161\/01.STR.0000131549.20581.ba","volume":"35","author":"MP LaMonte","year":"2004","unstructured":"LaMonte, M. P., Nash, M. L., Wang, D. Z., Woolfenden, A. R., Schultz, J., Hursting, M. J., & Brown, P. M. (2004). Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke, 35(7), 1677\u20131682.","journal-title":"Stroke"},{"issue":"2","key":"10066_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/STROKEAHA.115.011250","volume":"47","author":"T Wada","year":"2016","unstructured":"Wada, T., Yasunaga, H., Horiguchi, H., Matsubara, T., Fushimi, K., Nakajima, S., & Yahagi, N. (2016). Outcomes of argatroban treatment in patients with atherothrombotic stroke: observational nationwide study in Japan. Stroke, 47(2), 471\u2013476.","journal-title":"Stroke"},{"issue":"5","key":"10066_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi, Y., Tachi, T., & Teramachi, H. (2020). Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharmaceutical Research, 37(5), 86.","journal-title":"Pharmaceutical Research"},{"issue":"3","key":"10066_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan, S. K., & Hursting, M. J. (2000). The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy, 20(3), 318\u2013329.","journal-title":"Pharmacotherapy"},{"key":"10066_CR8","unstructured":"Argatroban package insert [Internet]. Retrieved December 18, 2016, from: https:\/\/www.gsksource.com \/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing Informating\/Argatroban\/pdf\/ARGATROBAN. PDF"},{"issue":"6","key":"10066_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1055\/s-0034-1390152","volume":"40","author":"HC Kwaan","year":"2014","unstructured":"Kwaan, H. C., McMahon, B. J., & Hylek, E. M. (2014). Age-related changes in thrombosis and hemostasis. Seminars in Thrombosis and Hemostasis, 40(6), 619\u2013620.","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"7","key":"10066_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrcardio.2012.61","volume":"9","author":"KA Arsenault","year":"2012","unstructured":"Arsenault, K. A., Hirsh, J., Whitlock, R. P., & Eikelboom, J. W. (2012). Direct thrombin inhibitors in cardiovascular disease. Nature Reviews Cardiology, 9(7), 402\u2013414.","journal-title":"Nature Reviews Cardiology"},{"issue":"4","key":"10066_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MBC.0b013e3282fe73ec","volume":"19","author":"R Siegmund","year":"2008","unstructured":"Siegmund, R., Boer, K., Poeschel, K., Wolf, G., Deufel, T., & Kiehntopf, M. (2008). Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagulation & Fibrinolysis, 19(4), 288\u2013293.","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"3","key":"10066_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11239-005-1849-9","volume":"19","author":"JR Bartholomew","year":"2005","unstructured":"Bartholomew, J. R., & Hursting, M. J. (2005). Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). Journal of Thrombosis and Thrombolysis, 19(3), 183\u2013188.","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10066_CR13","first-page":"180","volume":"04","author":"XJ Tang","year":"2007","unstructured":"Tang, X. J. (2007). Advances in the clinical use of argatroban. Thrombosis and Hemostasis, 04, 180\u2013182.","journal-title":"Thrombosis and Hemostasis"},{"issue":"14","key":"10066_CR14","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis, B. E., Wallis, D. E., Berkowitz, S. D., Matthai, W. H., Fareed, J., Walenga, J. M., Bartholomew, J., Sham, R., Lerner, R. G., Zeigler, Z. R., Rustagi, P. K., Jang, I. K., Rifkin, S. D., Moran, J., Hursting, M. J., & Kelton, J. G. (2001). Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103(14), 1838\u20131843.","journal-title":"Circulation"},{"issue":"6","key":"10066_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bjh.18153","volume":"197","author":"TE Warkentin","year":"2022","unstructured":"Warkentin, T. E. (2022). How to dose and monitor argatroban for treatment of HIT. British Journal of Haematology, 197(6), 653\u2013655.","journal-title":"British Journal of Haematology"},{"key":"10066_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13054-015-1109-0","volume":"19","author":"B Tardy-Poncet","year":"2015","unstructured":"Tardy-Poncet, B., Nguyen, P., Thiranos, J. C., Morange, P. E., Biron-Andr\u00e9ani, C., Gruel, Y., Morel, J., Wynckel, A., Grunebaum, L., Villacorta-Torres, J., Grosjean, S., & de Maistre, E. (2015). Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Critical Care (London, England), 19, 396.","journal-title":"Critical Care (London, England)"},{"issue":"21","key":"10066_CR17","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.3390\/jcm12216921","volume":"12","author":"TE Warkentin","year":"2023","unstructured":"Warkentin, T. E. (2023). Autoimmune heparin-induced thrombocytopenia. Journal of Clinical Medicine, 12(21), 6921.","journal-title":"Journal of Clinical Medicine"},{"issue":"24","key":"10066_CR18","first-page":"2951","volume":"34","author":"Pharmaceutical Administration Committee of Chongqing Hospital Association","year":"2023","unstructured":"Pharmaceutical Administration Committee of Chongqing Hospital Association. (2023). Expert consensus on prescription review rules of anticoagulants. China Pharmacy, 34(24), 2951\u20132967.","journal-title":"China Pharmacy"},{"issue":"2","key":"10066_CR19","first-page":"e200122","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma, H., Zhang, Q., Gu, Y., Ji, X., & Duan, J. (2023). Argatroban resistance and successful adjunctive anticoagulation for cerebral venous sinus thrombosis with SERPINC1 mutation: A case report. Neurology: Clinical Practice, 13(2), e200122.","journal-title":"Neurology: Clinical Practice"},{"issue":"3","key":"10066_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan, S. K., & Hursting, M. J. (2000). The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, sex, and hepatic or renal dysfunction. Pharmacotherapy, 20(3), 318\u2013329.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10066_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1592\/phco.24.4.409.33168","volume":"24","author":"DR Williamson","year":"2004","unstructured":"Williamson, D. R., Boulanger, I., Tardif, M., Albert, M., & Gr\u00e9goire, G. (2004). Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy, 24(3), 409\u2013414.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10066_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","volume":"267","author":"K Stahl","year":"2020","unstructured":"Stahl, K., Rastelli, E., & Schoser, B. (2020). A systematic review on the definition of rhabdomyolysis. Journal of Neurology, 267(4), 877\u2013882.","journal-title":"Journal of Neurology"},{"issue":"8","key":"10066_CR23","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.016","volume":"27","author":"H Oguro","year":"2018","unstructured":"Oguro, H., Mitaki, S., Takayoshi, H., Abe, S., Onoda, K., & Yamaguchi, S. (2018). Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke. Jounal of Stroke and Cerebrovascular Diseases, 27(8), 2175\u20132181.","journal-title":"Jounal of Stroke and Cerebrovascular Diseases"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10066-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10066-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10066-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:02:50Z","timestamp":1770476570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10066-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10066"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10066-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6926401\/v1","asserted-by":"object"}]},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}